BHV3000-312: Phase 3, Multicenter, Randomized, Double-blind, Group Sequential, Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant for the Treatment of Migraine (With or Without Aura) in Children and Adolescents 6 to <18 Years of Age

Grants and Contracts Details

StatusActive
Effective start/end date12/6/212/14/24

Funding

  • Syneos Health LLC: $61,183.00